https://www.yiliao.com/index.php?action=history&feed=atom&title=TNF%E6%8A%91%E5%88%B6%E5%89%82
TNF抑制剂 - 版本历史
2026-04-18T15:37:24Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=TNF%E6%8A%91%E5%88%B6%E5%89%82&diff=314642&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T05:24:02Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[TNF抑制剂]]</strong>（<strong>[[TNF Inhibitors]]</strong>）是一类通过抑制<strong>[[肿瘤坏死因子α]]</strong>（<strong>[[TNF-α]]</strong>）生物活性的生物制剂。[[TNF-α]]是人体内最重要的促炎[[细胞因子]]之一，在调节免疫应答和细胞凋亡中起中枢作用。当[[TNF-α]]过度表达时，会引发慢性的组织损伤和系统性炎症。[[TNF抑制剂]]通过与[[TNF-α]]特异性结合，阻断其与细胞表面受体（[[TNFR1]]/[[TNFR2]]）的交互，从而精准拦截炎症级联反应。该类药物是治疗<strong>[[类风湿关节炎]]</strong>、<strong>[[强直性脊柱炎]]</strong>、<strong>[[银屑病]]</strong>及<strong>[[克罗恩病]]</strong>等自身免疫性疾病的里程碑式疗法，显著降低了相关疾病的致残率和病死率。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[TNF抑制剂]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Anti-TNF Therapy]] / [[生物制剂]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[TNF抑制剂]]与TNF-α结合模型示意</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[TNF-α]] (7124)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7124([[TNF]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">11892</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P01375</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[单抗]]/[[融合蛋白]]/[[Fab片段]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量范围</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">91 kDa - 150 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">主要给药途径</th><br />
<td style="padding: 12px; color: #0f172a;">[[皮下注射]] / [[静脉滴注]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断炎症信号传导</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[TNF抑制剂]]的作用核心在于破坏[[TNF-α]]与其受体之间的信号连接。根据分子结构的不同，其拦截方式可分为三类：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>可溶性配体中和：</strong>如[[阿达木单抗]]、[[英夫利昔单抗]]，通过高亲和力结合循环中的可溶性[[TNF-α]]，使其无法接触细胞膜表面的[[TNFR]]，从而熄灭炎症火种。</li><br />
<li style="margin-bottom: 12px;"><strong>跨膜型TNF拦截：</strong>全抗体结构的抑制剂还能结合表达在细胞表面的膜型[[TNF-α]]，通过[[ADCC]]或[[CDC]]效应调节产生炎症因子的免疫细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>诱饵受体竞争：</strong>如[[依那西普]]，这是一种可溶性[[TNFR2]]与[[IgG1]] [[Fc段]]的融合蛋白，它作为“诱饵”竞争性结合[[TNF]]，模拟内源性调节机制。</li><br />
</ul><br />
<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">主流[[TNF抑制剂]]临床矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">通用名</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">结构类型</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">药代动力学特征</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a;">核心差异</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[阿达木单抗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">全人源单抗 (IgG1)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">半衰期约10-20天</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">免疫原性低，适应症覆盖最广。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[依那西普]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">受体-Fc融合蛋白</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">半衰期约3-5天</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">起效快，代谢快，安全性高。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[赛妥珠单抗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">聚乙二醇化Fab'</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">约14天</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">不通过胎盘，妊娠期安全首选。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[英夫利昔单抗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">人鼠嵌合单抗</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">需静脉滴注</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">剂量可调节，适用于重症肠病。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：规范化使用与风险监控</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[TNF抑制剂]]虽然效力强大，但在应用过程中需严密遵循安全性路径：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>结核与肝炎筛查：</strong>[[TNF-α]]是人体抵抗[[结核分枝杆菌]]的关键，抑制该因子可能导致潜伏结核复燃。启动治疗前必须进行[[T-SPOT]]和[[乙肝]]五项筛查。</li><br />
<li style="margin-bottom: 12px;"><strong>感染风险预警：</strong>治疗期间患者对细菌、真菌的防御力下降，需警惕严重的[[上呼吸道感染]]及皮肤软组织感染。</li><br />
<li style="margin-bottom: 12px;"><strong>继发性失效管理：</strong>部分患者因产生[[抗药物抗体]]（ADA）导致药效减退。临床建议定期进行[[治疗药物监测]]（[[TDM]]），必要时联用[[甲氨蝶呤]]（[[MTX]]）以降低免疫原性。</li><br />
<li style="margin-bottom: 12px;"><strong>特殊人群决策：</strong>心功能不全（[[NYHA]] III/IV级）及有[[多发性硬化]]等脱髓鞘病变的患者应禁用或慎用。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[TNF-α]]：</strong>炎症风暴的核心调节因子，由[[TNF]]基因编码。</li><br />
<li style="margin-bottom: 8px;"><strong>[[生物类似药]]：</strong>指在质量、安全性和有效性上与原研药高度相似的生物制品。</li><br />
<li style="margin-bottom: 8px;"><strong>[[细胞因子风暴]]：</strong>在某些重症状态下[[TNF-α]]等因子失控释放的危重状态。</li><br />
<li style="margin-bottom: 8px;"><strong>[[JAK抑制剂]]：</strong>如[[托法替布]]，是[[TNF抑制剂]]失效后的口服替代方案。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Feldmann M, Maini RN. (2001).</strong> <em>Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?</em> <strong>[[Annual Review of Immunology]]</strong>. 19:163-96.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：揭示了TNF在关节炎中作为上游因子的决定性作用，奠定了生物治疗的基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Tracey D, et al. (2008).</strong> <em>Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.</em> <strong>[[Pharmacology & Therapeutics]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：系统比较了不同分子构型抑制剂在结合动力学及细胞毒效应上的细微差异。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[TNF抑制剂]] 调控生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TNF-α]]•[[TNFR1]]•[[TNFR2]]•[[NF-κB]]•[[IL-1]]•[[IL-6]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[阿达木单抗]]•[[依那西普]]•[[欣普尼]]•[[赛妥珠单抗]]•[[希敏佳]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[AbbVie]]•[[Amgen]]•[[杨森]]•[[嘉和生物]]•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[针对中枢神经系统的TNF抑制剂研发]]•[[口服小分子抗TNF药物]]•[[针对细胞因子风暴的急性干预]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164